Author:
OncoTherics has successfully completed a sophisticated cross-species in vitro metabolism study designed to evaluate any difference between OCT1004 and its next generation isotopolog OCT1002 in terms of metabolic clearance and metabolite patterns.
The company is now seeking funding to continue the final PKPD equivalence studies and subsequent progression to clinical trials in the USA.
OncoTherics is currently raising first round funding. If you are interested in taking part, please provide your contact details so that we can include you on our contact list.
Are you working on a project where OncoTherics' technology might be of help or would you like to collaborate in our research? Please provide your contact details so that we can include you on our contact list.